DNA Repair Enzymes

• 

  Subject Areas on Research

  • A defined human system that supports bidirectional mismatch-provoked excision. 
  • A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. 
  • A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. 
  • A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. 
  • A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. 
  • Abasic sites in the transcribed strand of yeast DNA are removed by transcription-coupled nucleotide excision repair. 
  • Analysis of DNA mismatch repair proteins in human medulloblastoma. 
  • Analysis of the excision step in human DNA mismatch repair. 
  • Analysis of the proteins involved in the in vivo repair of base-base mismatches and four-base loops formed during meiotic recombination in the yeast Saccharomyces cerevisiae. 
  • Assembly and molecular activities of the MutS tetramer. 
  • Association and interactions between DNA repair gene polymorphisms and adult glioma. 
  • Atomic force microscopy captures the initiation of methyl-directed DNA mismatch repair. 
  • Attempted replication of 50 reported asthma risk genes identifies a SNP in RAD50 as associated with childhood atopic asthma. 
  • BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. 
  • Bidirectional excision in methyl-directed mismatch repair. 
  • Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. 
  • Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. 
  • Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. 
  • Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). 
  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways. 
  • Coordination and processing of DNA ends during double-strand break repair: the role of the bacteriophage T4 Mre11/Rad50 (MR) complex. 
  • DNA chain length dependence of formation and dynamics of hMutSalpha.hMutLalpha.heteroduplex complexes. 
  • DNA polymerase zeta introduces multiple mutations when bypassing spontaneous DNA damage in Saccharomyces cerevisiae. 
  • Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection. 
  • Direct visualization of asymmetric adenine-nucleotide-induced conformational changes in MutL alpha. 
  • Distinct functions of Nijmegen breakage syndrome in ataxia telangiectasia mutated-dependent responses to DNA damage. 
  • ERCC6/CSB gene polymorphisms and lung cancer risk. 
  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. 
  • Effects of hexavalent chromium on the survival and cell cycle distribution of DNA repair-deficient S. cerevisiae. 
  • Exonuclease 1 (EXO1) gene variation and melanoma risk. 
  • Expression of five selected human mismatch repair genes simultaneously detected in normal and cancer cell lines by a nonradioactive multiplex reverse transcription-polymerase chain reaction. 
  • Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. 
  • Extrahelical (CAG)/(CTG) triplet repeat elements support proliferating cell nuclear antigen loading and MutLα endonuclease activation. 
  • Formaldehyde-induced mutagenesis in Saccharomyces cerevisiae: molecular properties and the roles of repair and bypass systems. 
  • Functions of MutLalpha, replication protein A (RPA), and HMGB1 in 5'-directed mismatch repair. 
  • Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. 
  • Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair. 
  • Human exonuclease I is required for 5' and 3' mismatch repair. 
  • Human mismatch repair: reconstitution of a nick-directed bidirectional reaction. 
  • Hydrolytically deficient MutS E694A is defective in the MutL-dependent activation of MutH and in the mismatch-dependent assembly of the MutS.MutL.heteroduplex complex. 
  • Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • In vivo requirement for RecJ, ExoVII, ExoI, and ExoX in methyl-directed mismatch repair. 
  • Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. 
  • Initiation of methyl-directed mismatch repair. 
  • Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. 
  • Interactions of human mismatch repair proteins MutSalpha and MutLalpha with proteins of the ATR-Chk1 pathway. 
  • Interplay of catalysis, fidelity, threading, and processivity in the exo- and endonucleolytic reactions of human exonuclease I. 
  • Involvement of the beta clamp in methyl-directed mismatch repair in vitro. 
  • Involvement of two endonuclease III homologs in the base excision repair pathway for the processing of DNA alkylation damage in Saccharomyces cerevisiae. 
  • Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. 
  • MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. 
  • MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. 
  • MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. 
  • Mechanism of 5'-directed excision in human mismatch repair. 
  • Mechanisms of DNA-mismatch correction. 
  • Meiotic recombination involving heterozygous large insertions in Saccharomyces cerevisiae: formation and repair of large, unpaired DNA loops. 
  • Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. 
  • Methyl-directed mismatch repair is bidirectional. 
  • Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. 
  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. 
  • Mismatch repair-dependent iterative excision at irreparable O6-methylguanine lesions in human nuclear extracts. 
  • Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. 
  • MutLalpha and proliferating cell nuclear antigen share binding sites on MutSbeta. 
  • Mutation detection with MutH, MutL, and MutS mismatch repair proteins. 
  • Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. 
  • Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair. 
  • Nucleotide excision repair genes are expressed at low levels and are not detectably inducible in Caenorhabditis elegans somatic tissues, but their function is required for normal adult life after UVC exposure 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. 
  • Overlapping specificities of base excision repair, nucleotide excision repair, recombination, and translesion synthesis pathways for DNA base damage in Saccharomyces cerevisiae. 
  • Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. 
  • PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance. 
  • Polymorphisms of phase II xenobiotic-metabolizing and DNA repair genes and in vitro N-ethyl-N-nitrosourea-induced O6-ethylguanine levels in human lymphocytes. 
  • Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer. 
  • Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. 
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. 
  • Reaction mechanism of human DNA repair excision nuclease. 
  • Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. 
  • Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. 
  • Reduced expression of mismatch repair genes in colorectal cancer patients in Egypt. 
  • Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. 
  • Repair of DNA loops involves DNA-mismatch and nucleotide-excision repair proteins. 
  • Saccharomyces cerevisiae MutLalpha is a mismatch repair endonuclease. 
  • Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. 
  • Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. 
  • Structures of human exonuclease 1 DNA complexes suggest a unified mechanism for nuclease family. 
  • Suppression of DNA-damage checkpoint signaling by Rsk-mediated phosphorylation of Mre11. 
  • Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • The Rad50S allele promotes ATM-dependent DNA damage responses and suppresses ATM deficiency: implications for the Mre11 complex as a DNA damage sensor. 
  • The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2. 
  • Twenty-year survival in glioblastoma: a case report and molecular profile. 
  • Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23. 
  • Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. 
  • Yeast base excision repair: interconnections and networks. 
  • hSnm1B is a novel telomere-associated protein. 
  • p53: a two-faced cancer gene. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering